luye pharma group ltd

Luye Acquires Jialin for US$600 Million

Luye Pharma strengthens its position in China’s cardiovascular drug market with the US$600 million acquisition of Beijing Jialin Pharmaceutical.

Hanmi Licenses Poziotinib To Luye Pharma

Luye acquires the rights to Poziotinib, Hanmi's pan-HER inhibitor for the treatment of cancer.

Luye Raises US$764 Million With Hong Kong IPO

Luye Pharma has raised US$764 million through an IPO on the Main Board of the Stock Exchange of Hong Kong.